Dogwood Therapeutics Advances SP16 into Clinical Trials for Chemotherapy-Induced Pain
Event summary
- FDA accepted Dogwood Therapeutics' IND application for SP16 to treat chemotherapy-induced pain and neuropathy (CIPPN).
- SP16 Phase 1b trial, fully funded by a $2.5M NCI grant, will begin patient enrollment mid-2026 at the University of Virginia.
- Dogwood licensed SP16 from Serpin Pharma in September 2025 for royalty-free global development and commercialization.
The big picture
Dogwood Therapeutics is expanding its pipeline with SP16, targeting a high-incidence condition affecting 30-40% of chemotherapy patients. The FDA's IND acceptance positions the company to compete in the growing non-opioid pain management market, where demand for safer alternatives is rising. With Halneuron already in Phase 2b trials, Dogwood aims to consolidate its role in treating chemotherapy-induced neuropathic disorders.
What we're watching
- Clinical Progress
- The pace at which SP16 advances through Phase 1b trials will determine its viability as a non-opioid treatment for CIPPN.
- Market Differentiation
- Whether Dogwood can position SP16 alongside Halneuron to address broader chemotherapy-related symptoms beyond neuropathic pain.
- Funding Leverage
- How the NCI's $2.5M grant impacts future financing rounds and strategic partnerships for Dogwood.
Related topics